Artiva Biotherapeutics, Inc.
- Open
- 8.89
- Day high
- 10.12
- Day low
- 8.75
- Prev close
- 9.04
- Volume
- 358K
- Mkt cap
- $474M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.4
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $103.8M over the last 3 months (14 open-market buys, 5 sales)
- 🏛Institutions reducing (13F)
Artiva Biotherapeutics, Inc. (ARTV) is a Healthcare company listed on NASDAQ. The stock is up 308% over the past year. Over the trailing 3 months, insiders filed 14 open-market buys and 5 sales (SEC Form 4).
Artiva Biotherapeutics, Inc. (ARTV) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ARTV earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 8, 2026 | $-0.88 | $-0.95 | -8.0% | — | — |
| Nov 12, 2025 | $-0.92 | $-0.88 | +4.3% | — | — |
| Aug 6, 2025 | $-0.84 | $-0.87 | -3.6% | — | — |
| May 8, 2025 | $-0.68 | $-0.83 | -22.1% | — | — |
| Mar 25, 2025 | $-0.71 | $-0.66 | +7.0% | — | — |
| Aug 29, 2024 | $-4.40 | $-22.00 | -400.0% | $251000 | — |
| Jun 29, 2024 | — | $-0.62 | — | — | — |
| Dec 30, 2023 | — | $-0.30 | — | $33M | — |
| Sep 30, 2023 | — | $1.20 | — | $27M | — |
ARTV insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 14, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 6,552 | $8.94 |
| Jul 14, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 15,102 | $8.97 |
| Jun 29, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 1,876 | $8.98 |
| Jun 29, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 31,000 | $8.88 |
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 391,019 | $8.57 |
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 15,414 | $8.99 |
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 124,893 | $8.89 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 103 | $7.00 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 548,580 | $7.91 |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Buy | 479,039 | $6.91 |
| May 28, 2026 | GC Corp.10 percent owner | Buy | 1,085,069 | $11.52 |
| May 28, 2026 | GC Corp.10 percent owner | Buy | 347,222 | $11.52 |
| May 19, 2026 | Miralles Gines Diegoofficer: President & Head of R&D | Grant | 77,500 | — |
| May 19, 2026 | Aslan Freddirector, officer: Chief Executive Officer | Sell | 27,116 | $9.01 |
| May 19, 2026 | Banerjee Subhashisofficer: Chief Medical Officer | Sell | 7,037 | $9.01 |
Source: ARTV SEC Form 4 filings, latest Jul 14, 2026. For informational purposes only — not investment advice.
See the full ARTV insider & 13F page →Artiva Biotherapeutics, Inc. company profile
Overview
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company founded in 2019 and headquartered in San Diego, California. The company specializes in developing innovative cell-based therapies using natural killer (NK) cells to treat both autoimmune diseases and various forms of cancer. Since its incorporation, Artiva has focused on advancing a pipeline of off-the-shelf and engineered NK cell therapies, with its lead candidate AB-101 currently in clinical development for multiple indications including lupus nephritis, rheumatoid arthritis, and B-cell lymphomas.
Business
Artiva Biotherapeutics operates in the rapidly evolving field of cell therapy, specifically focusing on natural killer (NK) cell-based treatments. NK cells are a type of white blood cell that naturally exists in the human immune system and plays a crucial role in identifying and destroying abnormal cells, including cancer cells and cells involved in autoimmune responses. Unlike traditional pharmaceuticals that use chemical compounds, cell therapies involve taking living cells, modifying or enhancing them in laboratory settings, and then infusing them back into patients to treat disease. The company's approach centers on developing allogeneic therapies, meaning the NK cells come from healthy donors rather than the patients themselves. This "off-the-shelf" approach potentially offers significant advantages over autologous therapies (using the patient's own cells) by reducing treatment time, complexity, and cost while enabling broader patient access. Artiva's pipeline consists of three main product candidates. AB-101 represents the company's lead program - an unmodified, off-the-shelf NK cell therapy being developed for both autoimmune diseases (including lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, and ANCA-associated vasculitis) and hematologic cancers (particularly B-cell non-Hodgkin lymphoma). The company's oncology-focused candidates include AB-201, which involves NK cells engineered with chimeric antigen receptors (CARs) targeting HER2-positive cancers, and AB-205, a CAR-NK therapy targeting CD5-positive malignancies. CAR technology essentially programs the NK cells with synthetic receptors that help them better recognize and attack specific cancer cell markers.
Revenue model
As a clinical-stage biotechnology company, Artiva currently generates minimal revenue and operates primarily through research and development funding rather than product sales. The company's business model follows the typical biotech pathway of developing therapies through clinical trials with the ultimate goal of achieving regulatory approval and commercialization. Artiva's revenue streams are currently limited, with only $251,000 in revenue reported for 2024, likely from research collaborations or licensing arrangements. The company's primary funding comes from equity financing, having raised capital through public and private offerings to support its clinical development programs. The company's future revenue model will depend on successfully advancing its NK cell therapies through clinical trials and ultimately achieving regulatory approval. Potential revenue streams include direct product sales to hospitals and treatment centers, licensing agreements with pharmaceutical partners, and potentially manufacturing services for NK cell therapies. The company may also generate revenue through strategic partnerships where larger pharmaceutical companies provide upfront payments, milestone payments, and royalties in exchange for development and commercialization rights. Several factors could significantly impact Artiva's future profitability. Regulatory success represents the primary driver, as FDA approval for any of its therapies would unlock substantial revenue potential in markets worth billions of dollars. Manufacturing scalability will be crucial since cell therapies require complex, specialized production facilities that can be expensive to build and operate. Competition from other cell therapy companies, particularly those developing similar NK cell or CAR-T therapies, could pressure pricing and market share. Reimbursement policies from insurance companies and government healthcare programs will significantly influence market access and pricing power, as cell therapies typically carry high treatment costs that require payer approval.
Competitive moat
Artiva's competitive positioning in the NK cell therapy space presents both opportunities and challenges. The company's primary potential moat lies in its off-the-shelf approach using allogeneic NK cells, which could provide significant advantages over autologous cell therapies that require harvesting and modifying each patient's own cells. This approach potentially offers faster treatment initiation, lower costs, and broader patient accessibility compared to personalized cell therapies. However, Artiva's moat appears relatively narrow at this stage. The company faces intense competition from numerous well-funded biotechnology companies developing similar NK cell and CAR-T therapies, including larger players with more resources and established manufacturing capabilities. Fate Therapeutics, Celularity, and Nkarta are among the companies pursuing similar off-the-shelf NK cell approaches, while established CAR-T therapy companies like Gilead Sciences and Bristol Myers Squibb have significant advantages in manufacturing, regulatory experience, and commercial infrastructure. The company's intellectual property portfolio and clinical data will be critical in establishing differentiation. Artiva's focus on both autoimmune diseases and cancer could provide diversification benefits, as most competitors focus primarily on oncology applications. However, the company lacks the deep clinical validation, manufacturing scale, and regulatory track record that would constitute a strong competitive moat. Success will largely depend on demonstrating superior efficacy, safety, or cost-effectiveness compared to existing treatments and competing cell therapies, which remains to be proven through ongoing clinical trials.
Risks & safety
Artiva presents a mixed margin of safety profile typical of early-stage biotechnology companies, with strong liquidity but significant execution risks. • Liquidity position: Strong current ratio of 15.4x with $40.2 million in cash and short-term investments as of Q4 2024, providing adequate runway for near-term operations • Debt levels: Minimal debt burden with debt-to-equity ratio of only 0.08, indicating low financial leverage and solvency risk • Cash burn: High cash consumption with $55.7 million in negative free cash flow for 2024, suggesting approximately 2-3 quarters of runway at current burn rates • Valuation metrics: Trading at 0.6x price-to-book ratio, suggesting potential undervaluation relative to tangible assets, though negative earnings make traditional valuation metrics less meaningful • Market capitalization: Small market cap of approximately $51 million creates high volatility risk and limited institutional investor interest • Clinical risk: Primary risk lies in clinical trial outcomes, regulatory approval uncertainty, and competitive pressures in the crowded cell therapy space
Recent development
Based on the available financial data, Artiva has been primarily focused on advancing its clinical development programs while managing cash resources carefully. The company's revenue streams have remained minimal, with only $251,000 in revenue for 2024 compared to $33.5 million in 2023, suggesting the prior year included significant one-time payments likely from partnership or licensing agreements. The company has maintained a disciplined approach to cash management while continuing to invest in its core NK cell therapy programs. Operating expenses have remained relatively stable, with the company burning approximately $55 million in free cash flow during 2024 compared to $51 million in 2023. This consistency suggests focused execution on planned clinical milestones rather than expansion into new therapeutic areas. Artiva's balance sheet has been strengthened through equity financing activities, with total assets increasing significantly from $105 million at the end of 2023 to $210 million by Q4 2024. This capital infusion provides the company with enhanced financial flexibility to advance its lead programs, particularly AB-101, through critical clinical development phases. The company's current asset position of $189 million provides substantial working capital to support ongoing operations and clinical trial activities. The strategic focus appears to remain on advancing AB-101 through clinical development for both autoimmune and oncology indications, while maintaining development of the CAR-NK programs AB-201 and AB-205. The company's ability to maintain operations with minimal debt while advancing multiple clinical programs demonstrates disciplined capital allocation during this critical development phase.
ARTV company profile · for informational purposes only — not investment advice.
Track ARTV with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free